Trinity Biotech
TRIB
21 hedge funds and large institutions have $589K invested in Trinity Biotech in 2026 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 7 closing their positions.
33% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 3
1.06% less ownership
Funds ownership: 1.25% → 0.19% (-1.1%)
13% less capital invested
Capital invested by funds: $673K → $589K (-$84.4K)
16% less funds holding
Funds holding: 25 → 21 (-4)
43% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
YAG
Yorkville Advisors Global
Mountainside,
New Jersey
|
+$166K |
| 2 |
VF
Virtu Financial
New York
|
+$19.6K |
| 3 |
WN
Williams & Novak
Westlake Village,
California
|
+$10.6K |
| 4 |
HAIM
Hunter Associates Investment Management
Pittsburgh,
Pennsylvania
|
+$7.06K |
| 5 |
Wells Fargo
San Francisco,
California
|
+$1.83K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
-$14.8K |
| 2 |
TSS
Two Sigma Securities
New York
|
-$12.5K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$10.5K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
-$1.98K |
| 5 |
Renaissance Technologies
New York
|
-$1.83K |
TRIB Hedge Fund Activity: Q1 2026 in Review
21 of the 8,184 institutional investors tracked by Wall St. Rank reported a position in Trinity Biotech (TRIB) for Q1 2026, worth a combined $589K — down 13% from $673K a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of TRIB and 4 opened new positions — a net loss of 3 holders — while 3 trimmed existing stakes and 4 added.
The largest buyer was Yorkville Advisors Global, opening a new position worth an estimated $166K. The largest seller was Two Sigma Investments, exiting entirely with an estimated $14.8K sold.
- 21 institutional investors held Trinity Biotech (TRIB) as of Q1 2026, down from 25 in Q4 2025.
- Funds reported $589K of Trinity Biotech stock for Q1 2026, down 13% quarter-over-quarter.
- 4 funds opened new Trinity Biotech positions in Q1 2026 and 7 closed out, a net change of -3 holders.
- The largest Trinity Biotech buyer in Q1 2026 was Yorkville Advisors Global, an estimated $166K added.
- The largest Trinity Biotech seller in Q1 2026 was Two Sigma Investments, an estimated $14.8K sold.
Based on aggregated 13F filings for Q1 2026.